{"acquisitions":[],"changes":[],"country":"US","description":"ARTBIO develops alpha radioligand therapies that deliver targeted radiation directly to cancer cells. The therapies are designed for patients with solid tumors including prostate, non-small cell lung, pancreatic, and triple-negative breast cancers. It runs a proprietary Pb-212 isotope production platform spanning drug design, manufacturing.","domain":"artbio.com","employees":null,"founded":2021,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":42.365635,"lng":-71.104002,"location":"Cambridge, USA","multiples":[],"name":"Artbio","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":132000000,"connectionsAmong":[],"currency":"USD","date":"2025-07-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"artbio-com-2025-07-01-series-b","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-16","status":"attributed","url":null},"status":"attributed","type":"series-b","url":null}],"slug":"artbio-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-16","status":"attributed","url":null},{"fact":"existence","publisher":"artbio.com","retrievedAt":"2026-05-16","status":"self-reported","url":"https://artbio.com"},{"fact":"description","publisher":"artbio.com","retrievedAt":"2026-05-16","status":"self-reported","url":"https://artbio.com"}],"stage":"series-b+","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":["Netlify","Gatsby 4.25.9","React","Webpack"],"totalRaisedUsd":243000000,"traction":[],"updatedAt":"2026-05-16","valuations":[]}